Zymeworks Inc reports results for the quarter ended June 30 - Earnings Summary

• Zymeworks Inc ZYME.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of eight analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -58 cents to -38 cents per share.

• Revenue rose 153.2% to $48.73 million from a year ago; analysts expected $19.38 million.

• Zymeworks Inc's reported EPS for the quarter was 3 cents​.

• The company reported quarterly net income of $2.32 million.

• Zymeworks Inc shares had fallen by 1.1% this quarter and lost 15.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 37.6% above its last closing price of $12.16

This summary was machine generated from LSEG data August 8 at 04:22 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)